Research programme: CNS disorders therapeutics - Anavex Life Sciences

Drug Profile

Research programme: CNS disorders therapeutics - Anavex Life Sciences

Alternative Names: ANAVEX 1-41; ANAVEX 19-144

Latest Information Update: 09 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anavex Life Sciences
  • Class Furans; Small molecules
  • Mechanism of Action Calcium channel antagonists; Chloride channel modulators; Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists; NMDA receptor antagonists; Serotonin modulators; Sigma-1 receptor agonists; Sodium channel antagonists; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Major depressive disorder; Parkinson's disease; Stroke
  • Discontinued Epilepsy

Most Recent Events

  • 08 Jan 2015 Early pharmacodynamics data from a investigator-sponsored research in Neurological disorders released by Anavex
  • 12 May 2014 Discontinued - Preclinical for Epilepsy in Europe (unspecified route) prior to May 2014
  • 12 May 2014 Preclinical trials in Parkinson's disease in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top